The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL

Leukemia

Volumn 29, Issue 9, 2015, Pages 1811-1822

  Balakrishnan, K ^a   Peluso, M ^b   Fu, M ^a   Rosin, N Y ^a   Burger, J A ^a   Wierda, W G ^a   Keating, M J ^a   Faia, K ^b   O'Brien, S ^a   Kutok, J L ^b   Gandhi, V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Infinity Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; DUVELISIB; IBRUTINIB; IDELALISIB; INTERLEUKIN 10; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN BAD; PROTEIN KINASE B; S6 KINASE; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; IPI-145; ISOQUINOLINE DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL HOMING; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOTAXIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; EMPERIPOLESIS; FEMALE; HUMAN; HUMAN CELL; IC50; LEUKEMIA CELL; MALE; PATIENT HISTORY OF CHEMOTHERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CASE CONTROL STUDY; CELL SURVIVAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PHOSPHORYLATION; PROGNOSIS; SECRETION (PROCESS); STROMA CELL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; APOPTOSIS; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELL SURVIVAL; CHEMOKINE CCL3; CHEMOKINE CCL4; CHEMOTAXIS; FEMALE; HUMANS; ISOQUINOLINES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; PYRAZOLES; PYRIMIDINES; QUINAZOLINONES; RECEPTORS, ANTIGEN, B-CELL; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 84940790208     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.105     Document Type: Article

References (61)

1. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
2. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.
3. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
4. Deane JA, Fruman DA. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol 2004; 22: 563-598.
5. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140-156.
6. Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012; 10: 161.
7. Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG. Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol 2004; 173: 2236-2240.
8. Durand CA, Hartvigsen K, Fogelstrand L, Kim S, Iritani S, Vanhaesebroeck B et al. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 2009; 183: 5673-5684.
9. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002; 297: 1031-1034.
10. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 2004; 431: 1007-1011.
11. Okkenhaug K, Patton DT, Bilancio A, Garcon F, Rowan WC, Vanhaesebroeck B. The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol 2006; 177: 5122-5128.
12. Patton DT, Garden OA, Pearce WP, Clough LE, Monk CR, Leung E et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 2006; 177: 6598-6602.
13. Byrd JC, Woyach JA, Johnson AJ. Translating PI3K-delta inhibitors to the clinic in chronic lymphocytic leukemia: the story of CAL-101 (GS1101). Am Soc Clin Oncol Educ Book 2012; 32: 691-694.
14. Randis TM, Puri KD, Zhou H, Diacovo TG. Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. Eur J Immunol 2008; 38: 1215-1224.
15. Barbi J, Cummings HE, Lu B, Oghumu S, Ruckle T, Rommel C et al. PI3Kgamma (PI3Kgamma) is essential for efficient induction of CXCR3 on activated T cells. Blood 2008; 112: 3048-3051.
16. Chavakis E, Carmona G, Urbich C, Gottig S, Henschler R, Penninger JM et al. Phosphatidylinositol-3-kinase-gamma is integral to homing functions of progenitor cells. Circ Res 2008; 102: 942-949.
17. Martin AL, Schwartz MD, Jameson SC, Shimizu Y. Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. J Immunol 2008; 180: 2081-2088.
18. Del Prete A, Vermi W, Dander E, Otero K, Barberis L, Luini W et al. Defective dendritic cell migration and activation of adaptive immunity in PI3Kgammadeficient mice. EMBO J 2004; 23: 3505-3515.
19. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008-1018.
20. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/ refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390-3397.
21. Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013; 20: 1364-1374.
22. Okkenhaug K. Two birds with one stone: dual p110delta and p110gamma inhibition. Chem Biol 2013; 20: 1309-1310.
23. O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P et al. Duvelisib (IPI-145), a PI3K, inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 124: 3334-3334.
24. Porcu P, Flinn I, Kahl BS, Horwitz SM, Oki Y, Byrd JC et al. Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-kinase inhibitor, in patients previously treated with ibrutinib. Blood 2014; 124: 3335-3335.
25. Flinn I, Oki Y, Patel M, Horwitz SM, Foss FM, Sweeney J et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K inhibitor, in patients with relapsed. Refractory iNHL 2014; 124: 802.
26. Flinn I, Jager U, Offner F, Cymbalista F, Hallek M, Caligaris-Cappio F et al. DUO: a phase 3 trial of the PI3K-{delta},{gamma} inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ASCO Meeting Abstracts 11 June 2014; 32: TPS7122.
27. Horwitz SM, Flinn I, Patel MR, Younes A, Foss FM, Oki Y et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta}, {gamma}, in patients with relapsed/refractory lymphoma. ASCO Meeting Abstracts 17 June 2013; 31: 8518.
28. Patel MR, Kahl BS, Horwitz SM, Younes A, Foss FM, Oki Y et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta}, {gamma}, in patients with relapsed/refractory CLL. ASCO Meeting Abstracts 17 June 2013; 31: 7070.
29. Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG et al. Inhibition of PI3K and isoforms by IPI-145 in chronic lymphocytic leukemia overcomes signals from PI3K/AKT/S6 pathway and promotes apoptosis. Blood 2013; 122: 4167-4167.
30. Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 2014; 124: 3583-3586.
31. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG et al. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood 2010; 116: 1083-1091.
32. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182-1189.
33. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009; 114: 1029-1037.
34. Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Ivanyi J, Schmitz G et al. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 2009; 23: 2118-2128.
35. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-3612.
36. Marques M, Kumar A, Cortes I, Gonzalez-Garcia A, Hernandez C, Moreno-Ortiz MC et al. Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol 2008; 28: 2803-2814.
37. Nyberg P, Salo T, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 2008; 13: 6537-6553.
38. Marques M, Kumar A, Poveda AM, Zuluaga S, Hernandez C, Jackson S et al. Specific function of phosphoinositide 3-kinase beta in the control of DNA replication. Proc Natl Acad Sci USA 2009; 106: 7525-7530.
39. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-619.
40. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008; 1784: 159-185.
41. Banham-Hall E, Clatworthy MR, Okkenhaug K. The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 2012; 6: 245-258.
42. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-2088.
43. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591-594.
44. Barrientos JC, Furman RR, Leonard J, Flinn I, Rai KR, De Vos S et al. Update on a phase I study of the selective PI3K{delta} inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. ASCO Meeting Abstracts 2013; 31: 7017.
45. Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014; 123: 3406-3413.
46. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 2013; 31: 675-704.
47. Ali K, Camps M, Pearce WP, Ji H, Ruckle T, Kuehn N et al. Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 2008; 180: 2538-2544.
48. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG et al. Receptor tyrosine kinases and TLR/IL1 Rs unexpectedly activate myeloid cell PI3K gamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011; 19: 715-727.
49. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011; 117: 1662-1669.
50. Schall TJ, Bacon K, Camp RD, Kaspari JW, Goeddel DV. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med 1993; 177: 1821-1826.
51. Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ et al. Highlevel expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009; 113: 3050-3058.
52. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563-574.
53. Douglas MAK, Ted S, Allen K, Kahl BS, Horwitz SM, Flinn IW et al. Treatment with the potent PI3K inhibitor IPI-145 is associated with rapid decreases in specific cytokines, chemokines and matrix metalloproteinases in the serum of patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. ASH Annual Meeting 2013; Abstract # 1633.
54. Hayes GM, Busch R, Voogt J, Siah IM, Gee TA, Hellerstein MK et al. Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multicenter clinical studies. Leuk Res 2010; 34: 809-815.
55. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755-764.
56. IPI-145 shows promise in CLL patients. Cancer Discov 2014; 4: 136.
57. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000; 287: 1040-1046.
58. Os A, Burgler S, Ribes AP, Funderud A, Wang D, Thompson KM et al. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep 2013; 4: 566-577.
59. Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 2013; 122: 3010-3019.
60. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615-675.
61. Sawyer C, Sturge J, Bennett DC, O'Hare MJ, Allen WE, Bain J et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 2003; 63: 1667-1675.